抗转录因子Sp4自身抗体与抗TIF1γ抗体阳性皮肌炎患者癌症风险降低相关
研究采用噬菌体免疫沉淀测序从43例皮肌炎患者血清中发现转录因子Sp4为新自身抗原,并经ELISA在约翰霍普金斯371例肌炎患者、80例风湿病对照和200例健康对照中筛查抗Sp4抗体。结果显示抗Sp4抗体见于27例(10.5%)皮肌炎患者和1例(3.3%)类风湿关节炎患者,皮肌炎中96.3%的抗Sp4抗体存在于抗TIF1γ抗体阳性者。在抗TIF1γ阳性患者中,携带抗Sp4抗体者26例中无癌症,而未携带者35例中5例(14%,p=0.04)患癌;验证队列中携带抗Sp4抗体者15例中2例(13.3%)患癌,未携带者31例中21例(67.7%,p<0.001)患癌。结论认为抗Sp4自身抗体似乎识别出抗TIF1γ阳性皮肌炎患者中癌症风险较低的亚组。
要点
- 抗Sp4自身抗体主要见于抗TIF1γ抗体阳性的皮肌炎患者。
- 抗TIF1γ阳性皮肌炎中,携带抗Sp4抗体者26例均无癌症,未携带者35例中5例(14%)患癌。
- 验证队列中携带抗Sp4抗体者15例中2例(13.3%)患癌,未携带者31例中21例(67.7%)患癌。
核心结论
- 抗Sp4自身抗体似乎识别出抗TIF1γ抗体阳性皮肌炎患者中癌症风险较低的亚组。
研究设计与样本
- 研究采用噬菌体免疫沉淀测序使用43例皮肌炎患者血清发现转录因子Sp4为新自身抗原,并经患者血清免疫沉淀全长Sp4蛋白确认。
- 通过ELISA筛查约翰霍普金斯371例肌炎患者(255例皮肌炎、28例抗合成酶综合征、40例免疫介导坏死性肌病、29例包涵体肌炎、19例多发性肌炎)、80例风湿病对照(25例干燥综合征、25例系统性红斑狼疮、30例类风湿关节炎)和200例健康对照的抗Sp4自身抗体。
- 另对匹兹堡大学46例抗TIF1γ抗体阳性患者血清验证队列筛查抗Sp4自身抗体。
主要发现
- 抗Sp4自身抗体见于27例(10.5%)皮肌炎患者和1例(3.3%)类风湿关节炎患者,其他临床组未检出。
- 皮肌炎患者中96.3%的抗Sp4自身抗体存在于抗TIF1γ抗体阳性者。
- 抗TIF1γ阳性且携带抗Sp4抗体的26例患者中无癌症(0%),而未携带抗Sp4抗体的35例中5例(14%,p=0.04)患癌。
- 验证队列中抗TIF1γ阳性且携带抗Sp4抗体的15例中2例(13.3%)患癌,而未携带抗Sp4抗体的31例中21例(67.7%,p<0.001)患癌。
关键数值与推荐
- 抗Sp4自身抗体在皮肌炎患者中检出率为10.5%(27例),在类风湿关节炎患者中为3.3%(1例)。
- 皮肌炎中抗Sp4自身抗体与抗TIF1γ抗体的共存比例为96.3%。
- 抗TIF1γ阳性患者中,携带抗Sp4抗体者癌症比例0%(26例中0例)vs 未携带者14%(35例中5例),p=0.04。
- 验证队列中,抗TIF1γ阳性患者携带抗Sp4抗体者癌症比例13.3%(15例中2例)vs 未携带者67.7%(31例中21例),p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In dermatomyositis (DM), autoantibodies are associated with unique clinical phenotypes. For example, anti-TIF1γ autoantibodies are associated with an increased risk of cancer. The purpose of this study was to discover novel DM autoantibodies. METHODS: Phage ImmunoPrecipitation Sequencing using sera from 43 patients with DM suggested that transcription factor Sp4 is a novel autoantigen; this was confirmed by showing that patient sera immunoprecipitated full-length Sp4 protein. Sera from 371 Johns Hopkins patients with myositis (255 with DM, 28 with antisynthetase syndrome, 40 with immune-mediated necrotising myopathy, 29 with inclusion body myositis and 19 with polymyositis), 80 rheumatological disease controls (25 with Sjogren's syndrome, 25 with systemic lupus erythematosus and 30 with rheumatoid arthritis (RA)) and 200 healthy comparators were screened for anti-SP4 autoantibodies by ELISA. A validation cohort of 46 anti-TIF1γ-positive patient sera from the University of Pittsburgh was also screened for anti-Sp4 autoantibodies. RESULTS: Anti-Sp4 autoantibodies were present in 27 (10.5%) patients with DM and 1 (3.3%) patient with RA but not in other clinical groups. In patients with DM, 96.3% of anti-Sp4 autoantibodies were detected in those with anti-TIF1γ autoantibodies. Among 26 TIF1γ-positive patients with anti-Sp4 autoantibodies, none (0%) had cancer. In contrast, among 35 TIF1γ-positive patients without anti-Sp4 autoantibodies, 5 (14%, p=0.04) had cancer. In the validation cohort, among 15 TIF1γ-positive patients with anti-Sp4 autoantibodies, 2 (13.3%) had cancer. By comparison, among 31 TIF1γ-positive patients without anti-Sp4 autoantibodies, 21 (67.7%, p<0.001) had cancer. CONCLUSIONS: Anti-Sp4 autoantibodies appear to identify a subgroup of anti-TIF1γ-positive DM patients with lower cancer risk.
引用
- Hosono Y, Sie B, Pinal-Fernandez I, et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies. Ann Rheum Dis. 2022. PMID: 36008132. doi:10.1136/ard-2022-222441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。